9^th International Conference and Exhibition on Traditional & Alternative Medicine May 20-21, 2019 Osaka, Japan

Biography:

Peteris Trapencieris has completed his PhD at the age of 30 years from Latvian Institute of Organic Synthesis (LIOS) and postdoctoral studies from University Wisconsin (Madison, USA). He is the head of Department of Organic Chemistry at LIOS. He is a co-author of two medicines – Mildronate and Leakadine. He has published more than 50 papers in reputed journals and has interests in epigenetics and chemistry of natural products. 

Abstract:

A new concept of multitarget epigenetic drugs for anticancer treatment is where one of the enzymes is from field of epigenetics. We do offer to check natural compound (olefins, polyphenols, terpenes) dual inhibitors, where both of them are influencing epigenetic reactions - phosphorylation, methylation or acetylation. We have started to employ the most specific histone (H3K27Me3) methylation target EZH2 and its active natural complex PRC2. First in vitro testing experiments have shown good EZH2 inhibition by some natural polyphenols and triterpenes.

Biography:

Thananchanoke Rattanathada has completed her Bsc in Pharmacy at the age of 24 years from Chulalongkorn University,  MBA at age of 29 years from City University, WA, USA and She is a PhD candidate at Chulabhorn International College of Medicine, Thammasat University, Thailand. She was a Pharmacist at  Bangkok Metropolitan Administration (BMA) Medical College and Vajira Hospital and responsible for pharmaceutical care in cancer patients for 14 years. She is now a lecturer at Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand

Abstract:

Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia with the highest incidence in northeastern Thailand.  Chemotherapy of this type of cancer is limited by the lack of effective chemotherapeutic drugs.  A series of previous in vitro and in vivo studies supports further research and development of Atractylodes lancea (Thumb) DC. (AL) as a potential candidate for the treatment of CCA as a crude ethanolic extract. The dried rhizome of AL in the family Compositae, has been used in Chinese (“Cang Zhu”), Japanese (“So-jutsu”), and Thai (“Khod-Kha-Mao”) traditional medicines for diverse pharmacological qualities including anticancer, antimicrobial activities, anti-inflammatory, and activities on gastrointestinal, central nervous, and cardiovascular systems. These traditional uses are explained by its properties in eliminating dampness, strengthening the spleen, expelling wind-cold from the superficial parts of the body, and relieving the common cold. Objective: The purpose of the research was to develop oral pharmaceutical formulation (capsule) of the standardized AL crude ethanolic extract for further clinical development in patients with CCA. Methods: Major steps included macroscopic and microscopic authentication of the AL rhizomes, preparation of standardized AL extract, preparation of oral pharmaceutical formulation (capsule) of the standardized AL extract, quantitative and qualitative analysis of the marker compound (atractylodin) in the formulated AL extract, evaluation of physicochemical and pharmaceutical properties of the formulated AL extract/capsule, and cytotoxicity evaluation of the formulated AL extract. Results: Results of all evaluations confirm satisfactory pharmaceutical properties of oral (capsule) formulation of the standardized AL extract. Conclusion: This study shows that the formulated AL extract passed the criteria for further clinical evaluation.

Biography:

Harveen Kaur is affilated from Arogyam Ayurvedic & Panchkarma Centre, India

Abstract:

Objective

The purpose of the presented work is to assess the role of lifestyle management and an indigenously developed polyherbal Ayurvedic formulation, Arogyam-DRT in treating upper respiratory tract allergies i.e. nasal allergy or allergic rhinitis.

Materials and Methods

Arogyam-DRT powder is a combination of Chitrak (Plumbago zylenica), Haridra (Curcuma longa), Praval Pishti (Coral calcium), Kalmegh chura (Andrographis paniculata), Pippali (Piper longum), Kant kari (Solanum virginianum), Amla (Phyllanthus emblica), Pushkarmool (Inula racemosa), and Sitopaladi churna, all constituting 1 gm of dose. Raw material for all the ingredients was purchased and converted to Arogyam-DRT formulation by SVM Pharmaceuticals, Talwara, Hoshiarpur (Punjab). All of these ingredients were pulverized and passed through sieve no. 60 to render a uniform size to prevent any demixing while subsequent handling.  The powdered ingredients were mixed thoroughly and filled in plastic bulk containers provided with a 5 gm tared spoon. These boxes were labelled with all desirable directions and precautions to be taken. The product has been named as Arogyma-DRT by innovators for which the prescribed dosage regimen is 5 gm thrice a day (tds). Along with the said treatment, patients were also advised some changes in their lifestyles. The components of lifestyle modification include-

1. Patients were advised to instill 2-3 drops of lukewarm cow’s ghee in nostrils every morning. They were advised to apply cow’s ghee specifically obtained from Sahiwal cow belonging to Zebu cattle breed.
2. They were also advised to do Tivar Bhastrika 15-20 minutes twice a day at least.
3. Nasal rinsing with saline water was also suggested to patients before bed.

Inclusion criteria: One of the most positive aspects of study was inclusion of patients of a broader age group who had already undergone surgeries of nose. The criteria for inclusion of the patients under study were as follows:

• The patients who had already undergone surgical interventions were also the part of study.
• Patients of all age group varying from 5 to 80 years of age were included for investigations.

For statistical treatment to find out a meaningful correlation between the tested regimen of treatment and the recovery of patients, Chi Square test was applied.

Results

The above said combination of polyherbs i.e. Arogyam-DRT, Indian breed Sahewal cow’s ghee in nostrils and Tivar Bhastrika pranayam in 500 patients produced convincing results.

Approximately 50% of the patients under treatment got cured permanently, 31% patients were relieved but later on recurrence of disease was observed (making a total of 81% relieved), whereas 19% patients didn’t respond to above said combination therapy and hence showed no results.

Since the population size under study was large, Chi-square test was applied to treat and analyze the data statistically. The null and alternative hypotheses were applied as follows-

Null hypothesis: there is no significant difference between the new and conventional treatment.

Alternate hypothesis:  there is significant difference between the new and conventional treatment.

The calculated value of Chi-Square was 24.30 whereas the table value was noted down as 3.84. As the calculated value of Chi-square was more than the table value, null hypothesis got rejected. A significant difference between the new and conventional treatment was observed statistically which proved Arogyam-DRT treatment superior to the conventional treatment for the effective management of upper respiratory tract allergies. Hence the test was found to be highly significant.

The results are attributed to the following phytoconstituents:

The roots and leaves of Plumbago zylenica contain plumbagin as a major component. It has been identified as significant bioactive component responsible for its anti-allergic activity.

Curcumin alleviates nasal symptoms (sneezing and rhinorrhea) and nasal congestion through reduction of nasal airflow resistance by exerting diverse immunomodulatory effects, including suppression of interleukins (IL-4, IL-8), and tumor necrosis factor α (TNF-α) and increased production of IL-10 and soluble intercellular adhesion molecule.

Phyllanthus emblica and Piper longum are reported to have immunomodulatory properties that are helpful in managing respiratory allergic disorders, especially in the paediatric age group.

Andrographolide present in Kalmegh chura has the anti-allergic activity which appears to be due to immunomodulation.

The mast cell stabilizing (antihistaminic) activity can be attributed to a great extent due to the presence of piperine in the formulation which has already been reported to possess this activity.

All of these herbs thus make an effective polyherbal therapy for the management of allergic disorders associated with respiratory tract.

Conclusion

It can be inferred from the results obtained that the formulation developed by Arogyam combined with life style modifications has shown positive results in getting nasal allergy patients permanently relieved from their sufferings. Furthermore, this unique polyherbal combination can prove to be a boom in the treatment of respiratory tract allergic disorders.

Biography:

Shih-Yu Lee has completed his PhD from National Defense Medical Center and postdoctoral studies from Imperial College London. He is a associate professor in National Defense Medical Center. He has published more than 25 papers in reputed journals.

Abstract:

The prevalence of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is 25% or above worldwide. However, the safe and effective agents for NAFLD/NASH still require further investigation. The present study aims to  investigate the hepatoprotective effect and mechanism of 4-acetylantroquinonol B (4AAQB), a natural ubiquinone derivative from the mycelium of Antrodia cinnamomea, in vitro and in vivo. Raw264.7 and HepG2 cells were treated with 4AAQB and then stimulated with LPS (0.1/1.0 μg/ml) for 24h. Endoplasmic reticulum (ER) stress and NLRP3 inflammasome were analyzed by western blotting in both cell lines. In vivo model, male C57BL/6 mice were fed with methionine/choline-deficient (MCD) diet along with vehicle or 4AAQB (10 mg/kg, IP, once a day) for 10 consecutive days. The plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured. The liver tissues were analyzed for histology (hematoxylin and eosin stain), oxidative stress markers, and proteins levels involved in ER stress, NLRP3 inflammasome, lipogenesis, autophagy, and inflammatory markers. We found that 4AAQB significantly suppressed LPS-induced ER stress and NLRP3 inflammasome activation in both of the in vitro models.  In addition, 4AAQB ameliorated MCD-induced NASH and down-regulated ER tress and NLRP3 inflammasome activation in vivo. Based on these data, 4AAQB treatment might be a tangible therapeutic strategy for NAFLD/NASH.